Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on November 10, 2020. The filing serves to announce the company's financial results for the quarter ended September 30, 2020. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Cincinnati, Ohio.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document states that the detailed financial results are contained in a press release furnished as Exhibit 99.1, which is not included in the provided text.
Material Changes
No material changes versus the prior comparable period are described in the text of this Form 8-K. The filing acts solely as a notification that the quarterly results have been announced and are available in the attached exhibit.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference in any other filing, except as expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in the body of this 8-K.
Investor Verification Checklist
- Verify the discrepancy between the requested company name (Whitehawk Therapeutics, Inc.) and the actual registrant (Aerpio Pharmaceuticals, Inc.).
- Retrieve and review Exhibit 99.1 (the press release) to obtain actual revenue, net loss, and cash position figures for the quarter ended September 30, 2020.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check the Nasdaq Capital Market listing status for the trading symbol ARPO.